ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash
PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. ("ZimVie") (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED"), an investment firm focused exclusively on healthcare industries.
Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730 million. The per share price represents a premium of 99% to the ZimVie 90-day volume-weighted average price (VWAP) of $9.57 per share.
"This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years," said Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie. "Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally."
"We're excited to partner with ZimVie and its talented team," said André-Michel Ballester, Managing Partner, at ARCHIMED. "The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter."
Approvals and Timing
The Board of Directors of ZimVie has unanimously approved the transaction. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie's stockholders and applicable regulatory approvals. The transaction is not subject to a financing condition. Prior to the deal's closing, ZimVie is operating business as usual, separately from ARCHIMED.
Upon completion of the transaction, ZimVie will become a privately held company and ZimVie's shares will no longer be listed on the NASDAQ stock exchange.
Go-Shop Period
Under the terms of the merger agreement, ZimVie, with the assistance of Centerview Partners, its financial advisor, may solicit proposals from third parties for a period of 40 days continuing through midnight, New York City time, on August 29, 2025. ZimVie does not anticipate disclosing any developments regarding this process unless and until its Board of Directors makes a decision with respect to a potential superior proposal. There can be no assurance that the solicitation process will result in a superior proposal.
Advisors
Centerview Partners is serving as exclusive financial advisor to ZimVie, and Cravath, Swaine & Moore LLP is serving as legal advisor. UBS Investment Bank is serving as exclusive financial advisor to ARCHIMED, and Latham & Watkins LLP is serving as legal advisor.
About ZimVie
ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to ...
